Biocon, European Union and Type 2 diabetes

Biocon share price jumps 5% on DCP nod for diabetes drug in European Union
The rise in Biocon share price came after it announced that the company and its European partner, Zentiva, have received a Decentralized Procedure (DCP) approval for Liraglutide in European Union
Biocon, Zentiva get EU approval for generic diabetes, weight management drug
The approval is for the generic versions of Victoza to treat Type-2 Diabetes and Saxenda used in the treatment of weight management
Biocon, Zentiva secure EU approval for generic diabetes and weight loss drugs
Biocon and Zentiva gain EU approval for generic Liraglutide, marking milestone in expanding complex generic medication portfolio.
Biocon, Zentiva gets Decentralized Procedure approval for generic diabetes, weight management drug in EU
Bangalore: Biocon and its European partner, Zentiva, have received a Decentralized Procedure (DCP) approval for its complex formulation, Liraglutide, in the European Union (EU).The approval is
Biocon and Zentiva Secure EU Approval for Diabetes and Weight Management Drug
Biocon Ltd, in collaboration with Zentiva, has obtained EU approval for the complex formulation Liraglutide, a generic version of Victoza and Saxenda, used to treat Type-2 Diabetes and weight management.
Biocon, Zentiva Get EU Approval for Generic Liraglutide to Treat Diabetes and Aid Weight Management
Biocon Limited, alongside its European partner Zentiva, has successfully obtained approval for their generic version of Liraglutide in the E..|News Track
Biocon, Zentiva Get EU Approval for Generic Diabetes Drug
Biocon and Zentiva receive EU approval for generic versions of Victoza (diabetes) and Saxenda (weight management). This marks a significant step in providing affordable treatment options for patients.
The Asian Age12m
Industry Leaders Honor Manmohan Singh for His Pivotal Role in 1991 Reforms
You loved this nation. And your service to it will long be remembered”. Kiran Mazumdar-Shaw, executive chairperson of ...
Biocon stock settles 5% higher after US drug regulator clears Bengaluru API facility unit, stock up 35% YTD
Shares of Kiran Mazumdar Shaw-led Biocon extended gains to settle five per cent higher on Tuesday, December 24, after the ...
cnbctv182d
Biocon shares end 5% higher after US drug regulator clears Bengaluru API unit
Biocon shares had gained earlier in the day after the company and its European partner Zentiva received a decentralised ...
Biocon jumps as Bengaluru unit gets VAI status from USFDA
Biocon rallied 4.63% to Rs 344.80 after it received an establishment inspection report (EIR) with a voluntary action indicated (VAI) status from the US drug regulator, for API facility located at ...
Daily1d
USFDA issues EIR for Biocon Bengaluru facility
Bengaluru: Biocon has received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from ...